Archive for August, 2020
- NETE transforming into pure-play electric vehicles company through merger with Mullen Technologies
- Reverse merger will allow Mullen stakeholders to acquire majority of newly formed company, accelerating process of Mullen going public
- EV sales growing at 25% per year on average, expected to account for over 20% of sales by 2030
Electric vehicle (“EV”) sales in the U.S. have been growing by an average of 25% per year (http://ibn.fm/Uy6ss) – stellar results when compared to the dismal 1.76% drop experienced by the entire industry in 2019 (http://ibn.fm/tIyK3). In a bold move aimed at maximizing shareholder value, Net Element (NASDAQ: NETE) recently announced its plans to divest itself of its payments processing business model and enter into the EV industry by executing a definitive merger agreement with Mullen Technologies Inc., a Southern California-based EV company. With seven retail locations in California and one in Arizona, Mullen plans to expand its operations in the U.S. following the merger by opening a manufacturing plant in West Plains, Washington and launching a luxury sports car – the Dragonfly K50 – in the first half of 2021 (http://ibn.fm/1Irsm).
Through the reverse merger, NETE plans to transform itself into a pure-play electric vehicle company, allowing the stakeholders of Mullen, a privately held company, to acquire a majority of the new stock, accelerate the process of taking Mullen public, and catalyze its operations in the United States.
“We feel, after considering an array of strategic alternatives, that the agreement with Mullen provides our shareholders with the most compelling opportunity,” said Net Element chairman and CEO Oleg Firer (http://ibn.fm/1bgrR). “We conducted an extensive search of companies that have disruptive technologies and believe that Mullen represents the best path forward.
“COVID-19 has created a unique set of challenges for our payment processing business, as many of our payment processing customers are located in the Northeast, which has been hit especially hard by the coronavirus. We expect that the merger with Mullen will create a new path forward that should reward our long-time shareholders.”
Electric vehicles are expected to exceed 20% of annual vehicle sales by 2030 (http://ibn.fm/pTbje) yet currently account for only 2% of sales at present, indicating that market penetration has barely started. The falling prices of EV batteries, changes in fuel regulations and electric vehicle mandates in countries like China are contributing to market shifts favoring EVs across all markets worldwide. Besides expectations that EVs will account for almost half (48%) of all passenger car sales in China by 2025, they are also expected to dominate municipal bus sales by 81%, commercial vehicle sales at 56%, and 31% of the medium commercial market, according to a report by BloombergNEF (http://ibn.fm/u22TJ).
Current and future projections for the EV market have prompted a deluge of investor interest in the space, evidenced by the superior share price performance of electric vehicle manufacturers when compared to their more conventional counterparts (http://ibn.fm/SZrNA). Through its merger with Mullen Technologies, Net Element expects to join other institutional investors in gaining early access to the rapidly growing EV market where revenue growth and earnings potential appear to be extremely promising.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Alzheimer’s disease has been a problem for many people since it leads to progressive memory loss and a degeneration of other essential mental abilities. Without early management, the disease can lead to dementia. Several tests have been put forward to try and detect this disease at its earliest stages.
However, the good news is that a novel and direct blood test could now offer better results as it can detect Alzheimer’s disease’s early symptoms. According to the researchers, despite detecting Alzheimer’s, the new blood test could also show other brain damage conditions such as multiple sclerosis and stroke.
The functioning of Alzheimer’s blood test
The test works in such a way that it detects conditions through the identification of neurofilament light chains (“LFC”). These are kinds of structural proteins that normally make up the internal neuron skeleton. The proteins leak into the cerebrospinal fluid circulating in the spinal cord and the brain, and leaks into the bloodstream when it is damaged. High levels of this protein in the blood always indicates there is a problem in the body. Furthermore, that also indicates that the spinal tap is not needed.
The trial of the novel blood test was conducted on a population of 400 individuals to try and find out the root cause of Alzheimer’s condition. The number included 247 individuals who had damaged genes suspected to cause Alzheimer’s. The individuals with the faulty genes also showed continuous rising levels of LFC. The study showed that the chances of affected individuals passing these conditions to their children were 50%.
Additionally, the test also indicated that Alzheimer’s could be detected 16 years earlier before it shows its first signs and symptoms. This could be a boost as it could enable physicians to focus on new treatments that could alter the onset of the disease in those with high LFC levels. The researchers also added that it could also be easy to incorperate testing of these diseases into the screening test in a neurology clinic.
The screening test was validated on people with Alzheimer’s condition because their brains undergo a lot of neurodegeneration. However, the screening test does not give specific signs and symptoms for this condition. Furthermore, high levels of LFC do not necessarily mean that you have Alzheimer’s disease, it could be a symptom that you are suffering from other different neurological ailments and injuries.
As biomed companies like DarioHealth Corp. (NASDAQ: DRIO) always say, lots of time and effort is needed during clinical trials before a test can be relied upon to give results upon which treatment decisions are made.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cancer awareness among the general public is essential and a foundation upon which cancer-control plans can be built. Cancer awareness and survival rates can be boosted by understating the existing problems and exploring possible solutions. This is the reason as to why a charity foundation in the UK has called for increased screening for cancer across several regions. The foundation has also retaliated that stalling the numbers being examined has been the main stumbling block in saving the lives of patients with cancer.
Comparative screening of cancer
It has been noted that cancer screening of individuals who see their general practitioners (“GPs”) with symptoms of cancer is the main reason why such countries have better survival rates than the UK. A complete reconstruction of how cancer is treated should therefore be implemented. Currently, for a patient to be screened, it is the doctors who can decide whether or not it is necessary and give consent.
To boost the cancer survival rates, several one-stop shops that operate free of the GP system need to be established to offer more screening opportunities. Primary care and GPs are the main elements of a sound health system, and they should be supported fully rather than being undermined. The GPs should also be empowered to refer suspected patients to secondary care to boost survival rates.
An expert in the Charity Foundation in the UK introduced a good cancer plan in the year 2000 though ten years later, it has not yielded results. If the program had picked on well, cancer survival rates in the UK would be five times better and the best in Europe. The expert added that poor performance in treating cancer has contributed to more cancer deaths in the UK.
According to the Charity Foundation, the continuous comparative deficiency in cancer outcomes was unraveled in the concord-3 studies. From the study, it was revealed that Sweden, Australia, Norway, and Denmark were much better than the UK when it came to survival rates. All the four countries were doing well in trying to contain the six common types of cancer than the UK.
Other factors that hindered the Charity Foundation’s efforts in battling the disease were lack of scanners.
It was noted that the UK was ranked number 35 out of 37 for the numbers of CT scanners available. To make matters worse, it was at rank 31 out of the 36 nations in terms of the MRI scanners available. Due to these factors, the Charity Foundation is creating awareness to help boost the survival rates of cancer patients. This state of affairs shows why the work being done by biomedical companies like Predictive Oncology (NASDAQ: POAI) is so important in getting needed treatment to cancer patients.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced unaudited financial results for the second quarter ended June 30, 2020. “As China’s economy begins to recover from the coronavirus pandemic, I am pleased to report that our company delivered outstanding results in the second quarter of 2020, with record high revenue, substantially reduced net loss, record high adjusted EBITDA and adjusted net income, as well as the highest gross profit for any second quarter in the company’s history,” said Jian “T.J.” Tang, CEO and co-founder of iClick, in the press release. “We reported total revenue of US$58.1 million for the quarter, an increase of 18% from the same period of last year, while our gross profit grew to US$16.6 million, up 22% from the second quarter of 2019. In the meantime, our net loss narrowed substantially to almost a break-even. Our adjusted EBITDA more than quadrupled to a new record of US$5.2 million. Our adjusted net income improved significantly to US$2.5 million in the second quarter of 2020, compared with adjusted net loss of US$0.7 million in the same period of 2019, reflecting greater economies of scale, enhanced operating efficiencies and improved cost controls.”
To view the full press release, visit http://nnw.fm/LGe4i
About iClick Interactive Asia Group Limited
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe.
For more information, please visit ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://nnw.fm/ICLK
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the additive manufacturing industry, today announced that it will host a virtual roadshow webinar at 1:00 p.m. Eastern Time on Wednesday, August 26, 2020. According to the update, the webinar will feature Sigma Labs CEO Mark K. Ruport as he presents an overview of the market opportunity and the company’s strategy to accelerate revenue growth. Interested parties may register at http://nnw.fm/KzxAA and join the virtual roadshow by dialing 1-877-407-9039 or 1-201-689-8470 (international) and entering conference code 13708912.
To view the full press release, visit http://nnw.fm/rqmgg
About Sigma Labs, Inc.
Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D(R) for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Cancer is one of the deadliest diseases affecting humans and is also ranked as one of the highest killer diseases. Since there is no specific drug that cures it, surgery has been used as a standard procedure in treating early forms of cancer to remove the tumors. However, in its advanced stages, chemotherapy always comes in to salvage the situation, though surgery is ever taken as a precaution to prevent cancer from recurring once it has been treated. Many patients have been subjected to chemotherapy as a treatment for cancer, but they never needed it in the real sense.
Benefits and dangers of chemotherapy
Chemotherapy can be unpleasant and dangerous though it can be improved. Groups of researchers are trying to improve the situation to come up with better ways of treating cancer. Researchers are coming up with a blood test that could determine if the patient has the risk of having a recurrence of cancer. While chemotherapy is an essential and life-saving treatment to cancer, patients should not receive it unnecessarily. Avoiding unnecessary chemotherapy will help reduce the severe ongoing side effects associated with it.
The new cancer blood test
The test works by identifying the circulating tumor DNA (ctDNA), which are the DNA fragments released by the tumor into the blood. The test helps patients avoid undergoing chemotherapy as it will indicate whether the patient has little or no ctDNA in their blood system. The absence of the ctDNA will suggest that the patient is at low risk of cancer relapse hence should not be subjected to chemotherapy.
The test will also bring a sigh of relief to cancer patients since initially, there was no reliable test that could indicate that a patient could have cancer recurrence risks. When patients are informed that they are at low chance, they will have peace of mind knowing they will not be subjected to chemotherapy.
The new cancer test is under trial to fully determine its effects and seal any gaps in case there are any. The test has so far been done on around 400 cancer patients, and the researchers are hoping that the number will increase as time goes by. The cancer blood test will be extended in testing other types of cancer, such as ovarian and bowel cancer, and the researchers are hoping to conclude the trials by early 2021. If all these trials are successful, chemotherapy will be a thing of the past and will only be used in unavoidable and crucial circumstances.
The possibility of giving patients treatment that they don’t really need may explain why entities like Genprex Inc. (NASDAQ: GNPX) go to great lengths before bringing a new solution to the market.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Mullen Technologies, an emerging electric vehicle (“EV”) manufacturer and technology company, which previously announced a definitive agreement to merge with Net Element (NASDAQ: NETE) in a stock-for-stock reverse merger, was featured in a recent Carscoops article. The piece titled, “New Tesla Model Y Rival Has Over 600 Miles Of Range,” describes some stiff competition Tesla Inc.’s (NASDAQ: TSLA) Model Y is about to face from electric crossovers, specifically Fisker Inc.’s (NYSE: SPAQ) Fisker Ocean, the Mercedes EQA and, new competitor, the Mullen MX-05. The article reads, “California-based U.S. startup Mullen Technologies is also joining the electric crossover bandwagon with the MX-05, the company’s second electric model following the Qiantu K50 K50 electric sports car. . . . Powering the Mullen MX-05 (Mazda might not be too happy about the model name) will be a 150-kWh solid-state battery developed by China-based engineering firm Linghang BOAO. Mullen says this will provide a driving range of over 500 miles, but doesn’t specify if this is based on EPA or NEDC range estimates. Based on results during independent testing, Mullen claims the battery technology will allow electric vehicles to travel 640 miles when cruising at 55 mph on a flat surface and 550 miles at a cruising speed of 75 mph. For comparison, the Tesla Model Y Long Range has 316 miles of range.” Other key players in the emerging electric vehicle space include ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO), Nikola Corp. (NASDAQ: NKLA), NIO Inc. (NYSE: NIO) and Workhorse Group Inc. (NASDAQ: WKHS).
To view the full article, visit http://ibn.fm/MoBbk
About Net Element
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprises (“SMEs”) in the United States and selected emerging markets. In the U.S., NETE aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, the company’s cloud-based restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omnichannel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017, the company was recognized by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies. For additional information about the company, visit www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- SRAX Inc. reported its 2Q2020 results on August 17, 2020
- Company reported revenues of $1.1 million, up 29% YoY with EBITDA rising by 35% YoY
- SRAX has been diligently implementing cost-savings measures, with operating cost reduction of 21% QoQ and 39% YoY
- Company has sought to bolster balance sheet, closing convertible debt offering of $16.1 million during quarter
- SRAX announced its acquisition of nearly $5 million in bookings across Sequire, BIGtoken platforms over the first six weeks of third quarter
SRAX (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, recently reported its results for the second quarter ending June 30, 2020. Despite a largely tumultuous quarter marked with widespread lockdowns amidst the COVID-19 virus, SRAX reported revenues up 29% year-over-year accompanied by a significant expansion in gross margins, driving quarterly EBITDA up 35% year-over-year (http://nnw.fm/0Wf4E). The results were a testament to SRAX’s diversified product portfolio, as extraordinary performance by the company’s investor intelligence platform, Sequire was matched by strong growth witnessed within its BIGtoken platform.
In addition to SRAX’s robust revenue and earnings growth, the company has continued making strides in lowering its overall expense profile, which saw operating expenses decline by 21% relative to the same period last year. SRAX has also worked towards bolstering its balance sheet strength by recently announcing the close of a $16.1 million convertible debt offering, putting the company in a strong cash position to accommodate future growth.
Sequire, SRAX’s SAAS investor intelligence platform, was only rebranded as such towards the end of the first quarter but has already garnered great popularity – with over 1 million investors and traders currently on its platform. Separately, the Company also revealed that Sequire had now seen 91 publicly listed companies subscribe to its platform, a remarkable 54% increase relative to the number of corporate subscribers at the end of 2019 – an explosion of growth largely driven by Sequire’s extensive range of services.
The Company’s management illustrated the platform’s potential by outlining one example, where a single corporate subscriber using Sequire has seen their number of individual shareholders skyrocket—from 3,000 to over 360,000 during their tenure on the platform. The trend has now led the Sequire SAAS platform to record six consecutive quarters of growth.
“The growth we experienced this last quarter and through today has been the fastest growth we have encountered as a public company. For the past six weeks we have closed close to $1M per week in business, mostly driven by our Sequire platform,” said SRAX CEO and founder Christopher Miglino. “Public issuers are seeing the benefits of the platform, and our data teams are gaining significant insights from that growth. Sequire now has over 1 million investors and traders, a significant portion of which are from the Robinhood platform.”
The positive growth within the Sequire business has been mirrored by SRAX’s BIGtoken platform, which has seen a number of advertisers sign up to gain access to the verified consumer insights provided by BIGtoken’s over 16.7 million users. SRAX revealed that they witnessed the likes of lottery.com, Singapore’s GroupM and consumer product giant Procter & Gamble sign up as clients over the course of the quarter with corporate advertisers increasingly looking to gain access to verified consumer data, which in turn could help them better reach and serve their audiences.
Impressively, the positive trend seems to have carried on, as Miglino revealed that the company had booked close to $5 million in sales between BIGtoken and Sequire over the first six weeks of the third quarter – a huge outperformance given that the company had earlier forecast $3 million in sales for the entire quarter, a target exceeded over the month of July alone.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) recently announced its receipt of a pivotal U.S. patent for “Sample Preparation Devices and Methods,” which expands its already significant intellectual property (“IP”) portfolio. This award increases Pressure BioSciences’ IP ownership to include 25 issued patents protecting its unique pressure-cycling technology (“PCT”) systems. The newly patented PCT MicroPestle (“MP”) is a critical addition to the company’s instruments and consumables product line. A recent article discussing this reads, “The PCT MP is the company’s most important and popular consumable to date, having a unique construction that seals and protects the sample while flexing to transfer immense pressures to the important samples being processed inside the MP tube. This, in turn, facilitates homogenization and precise physical and chemical preparation of biological samples, sometimes very small and hard-to-process specimens such as needle biopsies, small suspensions of cells, and laser micro-dissected tissue sections.”
To view the full article, visit: http://nnw.fm/0TyhD
About Pressure BioSciences Inc
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its Soluble Biotech division has finalized its first major contract since being acquired by POAI earlier this year. The contract calls for a project involving protein expression followed by solubility studies, both areas of expertise for Soluble Biotech. The new POAI division provides soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” said former NASA astronaut and Soluble Biotech founder Dr. Larry DeLucas in the press release. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies. With our first contract on the books, and expanded capacity, the future is bright. We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”
To view the full press release, visit http://ibn.fm/QGzOs
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its Soluble Biotech division has finalized its first major contract since being acquired by POAI earlier this year. The contract calls for a project involving protein expression followed by solubility studies, both areas of expertise for Soluble Biotech. The new POAI division provides soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” said former NASA astronaut and Soluble Biotech founder Dr. Larry DeLucas in the press release. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies. With our first contract on the books, and expanded capacity, the future is bright. We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”
To view the full press release, visit http://ibn.fm/QGzOs
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
For the owner of an electric vehicle, the question that may always be lingering on your mind is: is it easy charging my cells on the road while traveling? Your wish is always to have a successful day with your car rather than endlessly looking for charging stations. However, it has been noted that most of these charging stations for EVs are either not working or are unavailable. Cities can still give the drivers a sigh of relief by establishing these charging stations. By doing the following, several cities can beat the threshold in developing these infrastructures for EV drivers.
Establishing driver-friendly charging destinations
Cities need to develop stations that are suitable for different models of EVs. The charging process should also be fast and of a high standard depending on the location of the driver. Several charging stations that are seen around are the on-street charging stations that are not convenient for many drivers. For instance, the towns should avail fast charging in the short term parking spaces for drivers who can pay higher fees, and moderate charging speeds for those drivers with lower packages. The stations can also adopt cloud-connection, enabling drivers to use smart apps in finding the nearest stations.
Choosing power with flexible terms
There is a big gap in most of the existing stations that contain the full operations of the back-end system. It is usually a web app allowing city operators to monitor and control the charging stations around that city. The charging stations can, therefore, communicate to the back-end system by use of an application protocol. For example, the city can use the Open Charge Point Protocol manageable charging station in managing all their charging stations.
Improving performance from behind the show
Since the back-end system controllers have a good outline of the network condition that is in use without leaving the premises, they can bring back the station online by troubleshooting.
Furthermore, they can respond to calls requesting deactivation of a charging period. Additionally, as the EV serves several drivers from different corners, the back-end system can easily manage the driver’s access and other billing issues that may arise.
Relying on a dependable partner
A big round of applause should be given to a vast and comprehensive experience in energy management. Cities need to work with companies that exceptional solutions for effective electric vehicle charging networks. For example, contact parking solutions which comprise of load management, network maintenance, and supervision are crucial when running EV charging stations.
Financial technology providers like Net Element Inc. (NASDAQ: NETE) can certainly come up with packages to make paying for EV charging services smooth and easy for car owners.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- NETE, Mullen Technologies sign definitive merger agreement
- Newly formed company will be dedicated to development of environmentally friendly, affordable technology offering energy solutions
- Agreement calls for Net Element’s wholly owned, newly formed subsidiary to acquire all outstanding shares of Mullen
Net Element (NASDAQ: NETE), a global financial technology and value-added solutions group, has signed a definitive merger agreement with Mullen Technologies Inc. The agreement outlines a stock-for-stock reverse merger plan resulting in Mullen, a privately held electric vehicle company, and its stockholders owning a majority of the outstanding stock in the post-merger company (http://ibn.fm/5LwBp).
“We are excited to move forward with the proposed merger with Mullen Technologies,” said Net Element executive chairman Oleg Firer. “We are confident that this transaction will increase shareholder value in the long term.”
The details of the newly inked merger agreement call for Net Element’s wholly owned, newly formed subsidiary to acquire all outstanding shares of Mullen. Once the merger is complete, Net Element shareholders will own 15% and Mullen shareholders will own 85% of the issued and outstanding shares of the combined company. The agreement also dictates that Net Element has the right to acquire up to an additional 6.7% of the combined company dependent on the amount of loans from Net Element to Mullen prior to closing.
In addition, the agreement notes that, just prior to the completion of the merger, Net Element will divest itself of its payments-processing business and portfolio, pending approval of the company’s stockholders. The completion of the merger itself is also subject to shareholder and NASDAQ approval, as well as other conditions outlined in the agreement.
Based in Southern California, Mullen Technologies is a licensed electric vehicle company with international distribution that operates in a variety of businesses focused on the automotive industry, including Mullen Automotive, Mullen Energy, Mullen Auto Sales, Mullen Funding Corp. and CarHub.
“Our team at Mullen Technologies is very proud to take the next step in completing this acquisition of Net Element,” said Mullen founder and CEO David Michery. “Mullen is dedicated to the development of environmentally friendly, affordable technology that will bring energy solutions to consumer products and communities in the near future. This acquisition provides the resources that Mullen can utilize to execute on its business model to integrate state-of-the-art, clean-battery technology into personal and commercial vehicles, and eventually sustainable, reusable battery technology into everyday consumer products.”
Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, today announced that it is making a number of changes to its management team in order to reduce costs, flatten the organizational structure and focus on the ongoing growth of a new generation of U.S. uranium and rare earth element (“REE”) professionals. “While the U.S. uranium mining and rare earth element industries are small, there are excellent opportunities, and we have some extremely talented and knowledgeable rising professionals who have shown a true dedication to the values we uphold at Energy Fuels, including safety, environmental protection, social responsibility, meeting and exceeding regulatory standards, creativity, and continuous improvement,” Energy Fuels’ president and CEO Mark S. Chalmers stated in the news release. “This is the reason why I am proud to announce the promotions of Scott Bakken, Bernard Bonifas, Dee Ann Nazarenus and Logan Shumway. I am also very pleased to introduce Sarai Luksch to the team. These individuals will be the leaders of our industry in the years and decades to come, and I look forward to witnessing their continued professional growth as we work to bring U.S. uranium and rare earth production back to global prominence.”
To view the full press release, visit http://ibn.fm/hlaZ3
About Energy Fuels
Energy Fuels is the leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers – the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill, the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
Some two novel urine tests have been developed that will improve the patients’ outcome for bladder cancer. These tests are significant upgrades of the existing urine tests for bladder cancer. The current urine tests have been inaccurate, invasive, and expensive.
Causes of bladder cancer
Bladder cancer has been causing high death rates as compared to other types of cancer. The many deaths are due to the difficulties and complications in detecting the cancer. Some tests from specific biomarkers have been used and have been giving high rates of false information. The usual methods that have been used over time have been cystoscopy. It involves inserting a camera into the urethra of a patient, which is unpleasant to a lot patients.
The latest urine tests can measure a gene variant called V1 that is elevated in the bladder of the patient who has bladder cancer. Furthermore, the gene extracts sections of the bladder wall, giving a chance for cancer tumors to grow there. It was discovered by Dr. Vinata Lokeshwar, one of the leading scientists at the Department of Molecular Biology and Biochemistry from Medical College of Georgia.
Detecting bladder cancer using the urine test
One of these tests works by measuring the levels of the enzymes that are created by V1. The second method works by measuring the amount of V1 in a patient’s system, depending on the mRNA excreted from urine. Both ways have an accuracy of about 90% in detecting bladder cancer.
These tests have proven to be more trustworthy when it involves high-grade tumors, boasting a 95% success rate in detecting bladder cancer. The piloting studies also gave a clear indication that the V1 test could have the capability of detecting the high-grade tumors. It could detect the tumors six months earlier than the invasive cystoscopy could do. These early detections could lead to increased survival among patients who have bladder cancer.
Using this simplified and accurate urine test for bladder cancer can also offer a patient ample recovery time and it helps in detecting any early forms of recurrence. However, these recurrences are always low in patients with low-grade bladder cancer. For patients with high-grade bladder cancer, their recurrence is always at 80% within three years, making it possible to detect it at the early stages. This is good news to patients who have bladder cancer as these two methods will be of great help to them in reducing mortality rates. Biomedical industry watchers say companies like DarioHealth Corp. (NASDAQ: DRIO) are also working to keep bringing better treatment options, so different patients can have hope that everything is being done to treat their ailments.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced its appointment of Rosie Cousino as director of Corporate Marketing. Cousino brings over 20 years of experience working with national brands, including Clorox, Del Monte Foods, Nature Made Vitamins, and, most recently, Medterra CBD. “Rosie is an accomplished CPG marketer and brings a wealth of experience and knowledge to our growing team,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “She brings a wide range of strategic brand-building knowhow to The Alkaline Water Company with insight across several CPG categories, including launching CDB products for a leading ingestible brand. Her deep digital experience and long history of building incredible brand strategies are precisely what our growing national lifestyle brands, Alkaline88, A88 flavor-infused, and A88CBD need.”
To view the full press release, visit http://cnw.fm/E9pTf
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused products include both the company’s lab-tested full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies. To purchase A88CBD(TM) products online, visit www.A88CBD.com. To learn more about The Alkaline Water Company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale, is sharing clarification regarding the expected number of shares that will be outstanding at closing of its pending merger with Mullen, if approved. The additional information was shared in a letter from NETE executive chairman and CEO Oleg Firer, which was released on Aug. 19, 2020. The letter noted that the merger agreement provides for a cap of 75 million outstanding shares at transaction closing, an amount that cannot be exceeded without approval from both parties. The letter also notes that this is a share maximum, with no way of knowing the actual number of outstanding shares at closing. “We continue working diligently on the pending merger with Mullen Technologies and we have taken steps to reduce operating expenses related to our payments processing business as we go through the process contemplated by the Merger Agreement,” Firer stated in the letter.
To view the full press release, visit http://ibn.fm/XRpYv
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprises (“SMEs”) in the United States and selected emerging markets. In the U.S., NETE aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, the company’s cloud-based restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omnichannel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017, the company was recognized by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies. For additional information about the company, visit www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Shares of iClick Interactive Asia Group Ltd. (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider connecting worldwide marketers with audiences in China, recorded a new 52-week high of $9.27 in early morning trading Wednesday. At time of publishing, shares of ICLK hover around $9.10 on above-average volume of over 1.69 million.
About iClick Interactive Asia Group Ltd.
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information, visit the company’s website at ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://nnw.fm/ICLK
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
There have been other pandemics that have been experienced globally before the coming of COVID-19. Also, it isn’t the only the headache the world is battling since there are other problems. For instance, drug-resistant illnesses and environmental degradation are other examples of disasters experienced globally. COVID-19 is gaining special attention due to its nature of rapid multiplication and spread.
Since the information gathering process is still ongoing, the current academic and scientific research cannot respond quickly to disasters like these. However, some ways can be used in overcoming this problem. For example, crowdsourcing is one best method that can be applied to boost biomedical research and development (R&D) and could provide results to tackle pandemics such as COVID-19.
Several promising responses to COVID-19 are ongoing, and several potential vaccines are undergoing various stages of development. However, there is no certainty that they will be successful after their development. Besides, the R&D under usage may not be adequate to inhibit this pandemic in the expected time.
Stopping COVID-19
Moving activities out of the already profitable and promising research can be the best way to end the pandemic. Moreover, for this to happen the scale of fighting the pandemic must be higher as compared to the extent of the outbreak. A profound reconstitution of the enticement of the biomedical research industry may be essential in shifting the activity from its usual profit-making into vaccine research.
Most academic research has provided suggestions on how this can be conducted. Typically, problems such as COVID-19 are always thoroughly researched to increase the probability of success in finding a cure or vaccine. For the process to be successful, new methods and technologies such as information science, biomedical crowdsourcing, and machine learning are essential.
These novel technologies have already shown their efficiency in biomedical research but not at the levels required to fight this pandemic. Crowdsourcing examples such as gamification where complicated biomedical problems are used as a basis for computer games to solve problems can be applied in such instances to help in managing this pandemic. Additionally, FOLDIt is effectively using proteins folding sets to solve problems similar to this.
Societal benefit ratio is also another meaningful way of thinking about crowdsourcing. It is the ratio of research and the efforts put into solving a problem that produces outcomes to the same problem. However, such issues do not always receive adequate problem-solving resources. For it to be addressed, the scale of investment should be equal to the magnitude of the problem.
How crowdsourcing operates
Technological advancements have made it easier to crowdsource solutions to biomedical problems. This is a problem-solving method that relies on putting data online as an open call for any person to solve it. A site such as InnoCentive always offers such platforms in solving their problems. Furthermore, InnoCentive has documented several successes by employing crowdsourcing in biomedical research.
It is also a cheaper and faster way of solving scientific problems as compared to relying on R&D departments. Governments should therefore come together and employ crowdsourcing to help fight this pandemic. Furthermore, crowdsourcing can be the best platform to be used by researchers to test the effectiveness in solving large scale problems such as COVID-19.
What do established biomedical firms like Genprex Inc. (NASDAQ: GNPX) think of this approach to solving major health challenges? One can only wonder!
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Shares of DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, reached a new 52-week high on Wednesday. In morning trading, the company’s shares reached a peak of $22.49 on volume of over 170,000, up from an opening price of $18.75. At time of publishing, shares of DRIO hover around $21.35, marking a PPS increase of roughly 13.87% on the day.
About DarioHealth Corp.
DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, visit www.dariohealth.investorroom.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://nnw.fm/DRIO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
There’s never been a better time to invest in cannabis, one private cannabis investment leader told the Investing News Network (INN).
Matt Hawkins, managing partner with cannabis-exclusive private investment firm Entourage Effect Capital, focuses mostly on the private side of the marijuana business, but said he is encouraged by the latest batch of quarterly results from leading companies in the public sector.
“We’ve been investing in the industry since 2014, we’ve made 66 investments I believe. There’s never been a better time to invest in the industry,” Hawkins said.
The partner pointed to the results of Trulieve (CSE:TRUL,OTCQX:TCNNF), TerrAscend (CSE:TER,OTCQX:TRSSF), Canopy Growth (NYSE:CGC,TSX:WEED) and Green Thumb Industries (CSE:GTII,OTCQX:GTBIF) as the bellwethers of the public arena, saying they have shown profitable improvements from the recent past.
“I think across the board it was a very good quarter,” the investor said.
Despite all the challenges to the economy, Hawkins said that the effects of the coronavirus have offered a chance for cannabis to stand up as an industry and gain territory amid the uncertainty.
Hawkins highlighted the cannabis sales seen in the US during lockdown times as an encouraging sign.
The investor added that he expects to see momentum pick up for discussions around legalization as the presidential election heats up in the country, regardless of the actual result of the race.
“We feel like there’s going to be an even further renewed push, no matter who gets elected in November, for legality both at the federal level and continued legality at the state level,” Hawkins said.
Those talks could also be fueled as more conservative US lawmakers realize that the revenue available from the cannabis industry by way of taxes is too tantalizing to pass up.
“I think even conservative-leaning folks on the right side of the aisle are starting to realize that this revenue is really just lost revenue,” Hawkins said.
Last week, a variety of companies, including Tilray (NASDAQ:TLRY), Sundial Growers (NASDAQ:SNDL), Zenabis Global (TSXV:ZENA), Canopy Rivers (TSX:RIV,OTC Pink:CNPOF) and The Green Organic Dutchman Holdings (TSX:TGOD,OTCQX:TGODF), all reported results to their investors and the market at large.
“We have focused on reducing costs, driving international revenue growth, mitigating COVID-19 related challenges, and improving our net loss and reported adjusted earnings before interest, taxes, depreciation and amortization (EBITDA),” Brendan Kennedy, CEO of Tilray, said in a statement announcing the company’s Q2 results.
The Tilray executive was referring to the cuts the firm has put in place as a way to restructure its operations. These changes started to spread in the Canadian cannabis industry well before the impact of the coronavirus reached the stock market.
“With our significant cost cutting and balance sheet actions behind us, we have positioned Tilray to enter the second half of 2020 in a stronger position,” Kennedy said. The firm is attempting to reach a breakeven or positive adjusted EBITDA level in Q4 of this year.
Tilray reported a 10 percent uptick in its revenue for the quarter compared to the same time period last year, thanks to strong sales from its international medical cannabis division.
However, this increase wasn’t enough to clear the previous quarter, in which the company generated C$70.7 million compared to the recent C$69.4 million result. Overall, Tilray posted a net loss of C$81.7 million for the quarter.
Fellow Canadian producer Canopy Growth released better-than-expected results thanks to a quarter-on-quarter increase in revenue.
“We are implementing a renewed corporate strategy with the appointment of a new leadership team which will focus on delivering quality products to our consumers,” said Canopy Growth CEO David Klein.
The company credited its results to strong medical sales in Canada and Germany. The net loss of Canopy Growth totaled C$128 million.
Similar to Tilray, Canopy Growth was also forced to make staff reductions and evaluate its spending.
Meanwhile, below the border, Trulieve continued its strong growth by posting total net income of US$6.6 million in its Q2 results, boosted by over US$120 million in revenue.
Kim Rivers, CEO of Trulieve, said she is looking forward to the development of the Florida market as the firm expects to have 68 stores by the end of the year.
In light of the recent results, Trulieve is increasing its yearly guidance to between US$465 million and US$485 million for revenue, and a range of US$205 million to US$225 million in adjusted EBITDA.
Fellow US corporation Green Thumb told investors that its US$222.2 million revenue number for the first half of 2020 surpasses its entire 2019 revenue tally.
“Demand is strong as cannabis continues to behave like a consumer staple,” Ben Kovler, founder and CEO of Green Thumb, said in a statement.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Thousands of researchers globally are working around the clock to develop a vaccine to attack the SARS-COV-2 virus. However, researchers in the nanoengineering laboratories are taking a different way towards dealing with the SARS-COV-2 infection. Besides boosting the immune system to attack and kill the virus, the researchers have opted to create a defense mechanism. The mechanism is to work by shielding healthy human cells that are affected by the virus. The strategy is straightforward as it employs the creating of decoy structures looking like the human cells that the SARS-COV-2 attacks. These decoy cells can then attract and later neutralize the virus, leaving the immune cells healthy.
For the decoy cells to be made, researchers gathered the outer membranes of immune or long cells and wrap them around a core designed from tiny, biodegradable particles. The decoy cells are made to resemble the human cells they are impersonating. These cells are also nanosponges as they can soak up any dangerous pathogens that may attack the cells they are impersonating. Once the virus is locked by these decoy cells, it cannot invade any cell, and the body’s defense system then eliminates it.
Why is this essential?
Vaccines are known to be vital in protecting the body against viral attacks. However, due to the nature of viruses mutating, vaccines and treatments are always rendered ineffective. This is the reason why every year, a new flu vaccine has to be developed. The good news is that the SARS-COV-2 does not mutate rapidly as other influenza viruses. However, why other mechanisms that are not affected by mutations must be put in place, hopefully, several teams of researchers should come up with safer and more effective methods of treating COVID-19 as fast as possible.
The unknown truth
Varieties of nanosponges that have been developed are at different levels of pre-clinical trials. Fortunately, the outcomes are very encouraging; however, there is still much to be done to ensure they are valid and safe for humans. Theses cellular nanosponges are the latest kinds of medicine to be developed. They have been designed from human red blood cell membranes. They are now at their latest stages of the regulatory processes as they have passed all stages of pre-clinical testing.
The way forward
Various companies are submitting new drug applications to the FDA for the red blood cell nanosponges to help in treating bacterial pneumonia. If the FDA approves the drugs, and the pre-clinical information for COVID-19 nanosponges continues to impress, it could be cleared for clinical trials. The nanosponges for COVID-19 are currently being tested on animals. If it reaches the clinical stage, there will be several ways of delivering that therapy.
For example, the therapies may be delivered directly into the intubated patients’ lungs through an inhaler or intravenous injection. Additionally, the immune-cell nanosponges could have the ability to soak up the inflammatory cytokine proteins in humans. These proteins are responsible for activating the dangerous immune system overreactions in some of the people suffering from COVID-19.
It would be enlightening to unpack what biomed companies like Predictive Oncology (NASDAQ: POAI) think about how soon these decoy cells would be available for use in patients.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal, has completed the sale of eight systems to a large university hospital organization in Virginia for a new surgical center. According to the update, the organization already has two STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 annual procedures.
To view the full press release, visit http://ibn.fm/mzHmo
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drives the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based roadmap for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Despite being illegal at the federal level, the state-legal cannabis industry has come quite a long way. As people shy away from pharmaceuticals and look towards more natural alternatives, more and more funds are being invested in researching marijuana and its effect on the human body. Next month, a documentary from Mad Machine Films will offer an in-depth look into the modern science behind cannabis, from the trailblazing scientists who pioneered cannabis research to all the lives that have been changed by the curative power of cannabinoids.
Directed by David Jakubovic, the film will be available in North America via multiple viewing platforms on August 25. It will feature various leaders of the medical cannabis movement, ranging from scientists and activists to patients. This includes Steve DeAngelo, the co-founder of Harborside Health Center in Oakland, one of the first and the largest medical cannabis dispensaries in the country.
“CBD Nation brings you the real science that decades of U.S. government-sponsored misinformation have hidden from public view. Watch it, and learn why cannabis may just be the most valuable medicine ever discovered by human beings,” he said during the press release for the documentary.
The documentary will also feature Israeli organic chemist Dr. Raphael Mechoulam who is widely considered the father of cannabinoid research. He and a team of scientists were the first to isolate, describe, and synthesize delta-9 THC, the chemical responsible for cannabis’ infamous high. He says that although cannabis has been known to have medicinal properties for more than three decades, the plant couldn’t be used to its true potential until the stories of patients whose lives were changed by medical cannabis gained mainstream attention. Mechoulam is now the President of the Center for Cannabinoid Research at the Hebrew University of Jerusalem.
“We published our findings thirty-seven years ago: cannabidiol (CBD) blocks epileptic attacks in patients. What happened? Nothing for thirty years. Nothing happened until desperate parents like those in this film did their own research and found that cannabidiol can help children with epilepsy. But epilepsy is just one of many conditions that we know cannabis medicine can treat. If the world chooses to not look at all of the science, it is not ignorance, it’s negligence.”
The film’s main stars will be the patients and families who fought for access to medical cannabis and ultimately set the ball rolling for the medical cannabis industry. Teenager Rylie Maedler, for instance, was diagnosed with a rare degenerative bone disease called aggressive giant cell granuloma that caused tumors that ate away at the bones of her face when she was 7. She is the only person with the disease whose bones have regenerated, and she has CBD to thank for that.
“I hope that U.S. doctors, educators, and politicians see this film because I’m living proof that cannabis and CBD have a place in modern medicine.” The documentary will be available in North America on August 25 via video-on-demand platforms and streaming services including Amazon and iTunes. Watch the trailer on YouTube.
Analysts think cannabis companies like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) will be hoping that the documentary triggers heightened interest in the benefits of cannabis compounds for both health and wellness.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) has announced that multistate CBD operator CBD Plus will carry its complete line of A88CBD(TM) topical and ingestible products. A producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, WTER has partnered with CBD Plus to carry the A88CBD product line in all 142 CBD Plus locations across Texas, Oklahoma, Florida, Tennessee, Kansas, Maryland, Georgia and Arkansas. In addition, A88CBD products can be found on CBD Plus’ online store. “Launching in 142 locations across multiple states with one of the fastest-growing premium CBD retailers is a significant step to expanding our A88CBD brand,” said The Alkaline Water Company president and CEO, Rickard Wright, in the press release. “We are starting to position the A88CBD brand as successfully as our flagship brand, Alkaline88. Interest in our growing lifestyle brands A88 and A88CBD remains very strong with a healthy pipeline of opportunities across multiple trades. Given the nascent nature of the industry, we are approaching all our partnerships with co-branding marketing opportunities, which is helping to establish our A88CBD brand in local markets.”
To view the full press release, visit http://cnw.fm/DT7FA
About The Alkaline Water Company Inc.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a digital marketing and consumer data-management technology company, today announced that its investor intelligence and communications platform, Sequire, has surpassed 1,000,000 active investors and traders from 91 public companies. “We are creating a community of public company executives that are taking back their data. For too long these leaders have relied on subpar data to make important capital market decisions,” SRAX founder and CEO, Christopher Miglino, stated in the news release. “Our clients have seen notable results from Sequire and our marketing services, and the more companies that join in our mission the better the platform gets at identifying and securing investors. The retail investor is becoming a bigger part of the cap table and we have mastered the connection between trading platforms such as Robinhood and the public issuer, just as these platforms attempt to become less transparent.”
To view the full press release, visit http://nnw.fm/gu2Tx
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Trxade Group (NASDAQ: MEDS) has continued to offer innovative medical consultation and prescription drug solutions and was answering today’s health care demands well ahead of COVID-19. Even before emergence of the pandemic, Trxade Group was introducing services that help independent pharmacies shop competitively for medications as well as help patients receive those medications promptly and safely and access medical providers through smart-tech secured applications. The company has further advanced measures to assist patients and providers continue to access resources through a virtual environment, all while its business model is gaining ground amid increased demand. A recent article discussing pandemic-driven growth of virtual health care reads, “During the COVID-19 crisis, telehealth services have seen astronomical expansion. Telehealth claims to private insurers have grown 4,347% year-over-year (http://nnw.fm/KdQP2), CVS Health saw 600% growth in telehealth and virtual visits through its MinuteClinics in the first quarter of 2020 (http://nnw.fm/iabaP), Blue Cross and Blue Shield of Tennessee saw 50 times more telehealth visits in May compared to their normal amount (http://nnw.fm/HoW3M), and Blue Cross of Idaho processed more than 90,500 telehealth claims between March and June, with telehealth now representing more than one-quarter of all claims (http://nnw.fm/z9xpo).”
To view the full article, visit: http://nnw.fm/rDJCy
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Net Element (NASDAQ: NETE), a global technology and value-added solutions group that supports electronic payments acceptance in a multichannel environment including point-of-sale (“POS”), e-commerce and mobile devices, has received a valuation by Zacks Small-Cap Research (“ZCR”). Among other highlights, the ZCR report cites NETE’s agreement to merge with Mullen Technologies, an electric vehicle assembler and manufacturer. The Mullen merger is anticipated to close in Q4 of 2020. The report reads, “Using the electric vehicle peer valuation of 10x EV/sales, and owning 15-21.7% of the post merger company the company could be worth $30.00 per share once the deal closes and twice that by 2023.”
To view the full report, visit http://ibn.fm/kRwJx
About Net Element, Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprises (“SMEs”) in the U.S. and selected emerging markets. In the U.S., it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, the company’s cloud-based restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omnichannel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017, the company was recognized by South Florida Business Journal as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Canopy Rivers (TSX: RIV) (OTC: CNPOF), today announced that it will hold its annual general and special meeting of shareholders of the company 10 a.m. EDT on September 24, 2020. The meeting will be held at the company’s offices; however, due to health concerns relating to the novel coronavirus and to comply with government and public health directives, Canopy Rivers is urging all shareholders to vote by proxy in advance of the meeting and is discouraging physical attendance. The meeting will be limited to registered shareholders and duly appointed proxyholders only. Shareholders who wish to access and ask questions at the meeting may do so by phone or audio-only webcast using the details provided in the update. In addition, an audio replay of the meeting will be available until October 24, 2020.
To view the full press release, visit http://cnw.fm/j5CtG
About Canopy Rivers Inc.
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. Canopy Rivers believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging its industry insights, in-house expertise, and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders with exposure to specialized and disruptive cannabis companies. The company’s mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, Canopy Rivers is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.
NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Canopy Rivers (TSX: RIV) (OTC: CNPOF) is a venture capital firm specializing in investing and helping build out innovative companies from across the cannabis value chain. The company’s portfolio is wide-ranging, including companies focused on applying agricultural innovations that improve the potential of cannabis and hemp plants, the processing of cannabis and hemp into finished products, creating devices and tools used to enhance the cannabis consumption experience as well as software designed to streamline supply chain management and improve brand visibility. Canopy Rivers’ venture capital & portfolio operations team works directly with their portfolio companies to further identify opportunities for collaboration within the Canopy Rivers ecosystem.
Narbé Alexandrian, President and CEO of Canopy Rivers Inc., will be on the panel titled “Stop Chasing & Start Attracting the Right VCs”. Attendees will get the inside scoop on what some of the top venture capitalists look for when evaluating a company as their next potential investment.
To learn more about Canopy Rivers, visit https://www.canopyrivers.com/
For registration information and further details on Benzinga’s Cannabis Capital Conference, visit https://www.benzinga.com/events/cannabis/detroit/
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured presentation.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations in 2020, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
